HIV-associated mitochondrial toxicity in pregnancy

Area of Science:

• Obstetrics and Gynecology
• Infectious Diseases
• Pharmacology

Background:

• Pregnancy involves significant physiological changes to support fetal development.
• Combination antiretroviral therapy (ART) with zidovudine has reduced perinatal HIV transmission.
• Concerns exist regarding potential mitochondrial toxicity associated with nucleoside analog reverse transcriptase inhibitors (NRTIs) during pregnancy.

Purpose of the Study:

• To review available data on NRTI-induced mitochondrial toxicity in mothers and newborns.
• To assess the potential long-term consequences of NRTI-containing ART during pregnancy.
• To examine the safety profile of ART regimens used for preventing mother-to-child HIV transmission.

Main Methods:

• Literature review of human and animal studies.
• Analysis of data on mitochondrial toxicity associated with NRTI use in pregnant individuals.
• Examination of ART regimens employed for preventing perinatal HIV transmission.

Main Results:

• Studies suggest a possible association between NRTI-containing ART and mitochondrial toxicity in newborns and mothers.
• Data on the long-term consequences of NRTI exposure during pregnancy remain limited.
• The efficacy of ART in preventing perinatal HIV transmission is well-established.

Conclusions:

• While ART significantly reduces perinatal HIV transmission, potential NRTI-induced mitochondrial toxicity warrants further research.
• Long-term monitoring of maternal and infant health is crucial for understanding the full impact of these therapies.
• Further studies are needed to elucidate the mechanisms and clinical significance of NRTI-related mitochondrial dysfunction in pregnancy.